Free Trial

Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

Regeneron Pharmaceuticals logo
$711.37 +9.52 (+1.36%)
(As of 09:51 AM ET)

Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
6
Buy
16

Based on 23 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 1 has given a sell rating, 6 have given a hold rating, 15 have given a buy rating, and 1 has given a strong buy rating for REGN.

Consensus Price Target

$1,052.90
48.01% Upside
According to the 23 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $1,052.90. The highest price target for REGN is $1,300.00, while the lowest price target for REGN is $165.00. The average price target represents a forecasted upside of 48.01% from the current price of $711.37.
Get the Latest News and Ratings for REGN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Regeneron Pharmaceuticals and its competitors.

Sign Up

REGN Analyst Ratings Over Time

TypeCurrent Forecast
12/24/23 to 12/23/24
1 Month Ago
11/24/23 to 11/23/24
3 Months Ago
9/25/23 to 9/24/24
1 Year Ago
12/24/22 to 12/24/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
15 Buy rating(s)
17 Buy rating(s)
16 Buy rating(s)
19 Buy rating(s)
Hold
6 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
6 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$1,052.90$1,099.55$1,118.62$908.12
Forecasted Upside48.01% Upside48.99% Upside6.94% Upside7.25% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

REGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Regeneron Pharmaceuticals Stock vs. The Competition

TypeRegeneron PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.70
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside50.02% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Neutral News

See Recent REGN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/17/2024Canaccord Genuity Group
5 of 5 stars
J. Newman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
12/10/2024Bank of America
3 of 5 stars
 Reiterated RatingUnderperform$565.00-28.30%
11/15/2024Wolfe Research
3 of 5 stars
 Initiated CoverageOutperform$1,150.00+46.96%
11/14/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$895.00+11.27%
11/6/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$1,150.00 ➝ $1,000.00+20.56%
11/1/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$1,260.00 ➝ $1,215.00+44.97%
11/1/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$1,235.00 ➝ $1,184.00+41.27%
11/1/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$1,080.00 ➝ $1,065.00+25.91%
11/1/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$1,300.00 ➝ $1,190.00+40.24%
11/1/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$1,137.00 ➝ $1,126.00+33.88%
11/1/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$1,242.00 ➝ $1,195.00+42.57%
10/24/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Kasimov
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$1,250.00 ➝ $1,175.00+24.93%
10/24/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$1,200.00 ➝ $1,150.00+22.16%
10/23/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$1,015.00 ➝ $1,015.00+7.77%
10/22/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$1,200.00 ➝ $1,050.00+9.11%
9/24/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/24/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Market Perform$1,175.00 ➝ $1,077.00-1.37%
8/2/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$1,180.00 ➝ $1,300.00+19.90%
7/23/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$1,030.00 ➝ $1,200.00+12.39%
6/25/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$1,060.00 ➝ $1,170.00+9.97%
4/17/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$1,090.00 ➝ $1,099.00+21.95%
3/12/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$1,125.00+16.65%
11/28/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$935.00 ➝ $937.00+17.00%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$800.00-2.77%
11/3/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$950.00+16.02%
9/15/2023Westpark Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
6/28/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade
6/28/2023500.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
6/28/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade
6/28/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$800.00 ➝ $760.00+6.13%
5/5/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/5/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$976.00 ➝ $895.00+17.59%
3/28/2023Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
3/23/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$853.00 ➝ $862.00+14.73%
1/30/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$775.00 ➝ $875.00+17.79%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 10:10 AM ET.


Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, December 18, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

Regeneron Pharmaceuticals
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

  • Regeneron Pharmaceuticals, Inc. has a strong consensus rating of "Moderate Buy" from analysts, indicating positive sentiment towards the stock's future performance.
  • The current stock price is $778.50, which is significantly lower than its 52-week high of $1,211.20, suggesting potential for price appreciation as the market recovers.
  • Seventeen analysts have assigned a buy rating to the stock, reflecting confidence in the company's growth prospects and product pipeline.
  • The company maintains a solid market capitalization of approximately $85.55 billion, which provides stability and resources for ongoing research and development.
  • Regeneron Pharmaceuticals, Inc. has a low debt-to-equity ratio of 0.09, indicating a strong balance sheet and lower financial risk, which is attractive to investors.

Regeneron Pharmaceuticals
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

  • Recent price target reductions by multiple analysts, including Oppenheimer lowering it from $1,150.00 to $1,000.00, may signal concerns about the company's near-term performance.
  • One analyst has rated the stock with a sell rating, which could indicate potential risks or challenges that investors should consider.
  • The stock has experienced significant volatility, with a 52-week low of $735.95, suggesting uncertainty in its price movements.
  • Regeneron Pharmaceuticals, Inc. has a price-to-earnings (P/E) ratio of 19.27, which, while not excessively high, may indicate that the stock is priced for growth, making it vulnerable to market corrections.
  • Recent downgrades from firms like Leerink Partners, which lowered their rating from "strong-buy" to "hold," may reflect a cautious outlook on the company's future performance.

REGN Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $1,052.90, with a high forecast of $1,300.00 and a low forecast of $165.00.

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There is currently 1 sell rating, 6 hold ratings, 15 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares.

According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 48.01% based on their 12-month stock forecasts.

Over the previous 90 days, Regeneron Pharmaceuticals's stock had 2 upgrades and 2 downgrades by analysts.

Analysts like Regeneron Pharmaceuticals less than other "medical" companies. The consensus rating score for Regeneron Pharmaceuticals is 2.70 while the average consensus rating score for "medical" companies is 2.81. Learn more on how REGN compares to other companies.


This page (NASDAQ:REGN) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners